CN107405325B - 用于组合疗法的药物组合物 - Google Patents

用于组合疗法的药物组合物 Download PDF

Info

Publication number
CN107405325B
CN107405325B CN201680015586.6A CN201680015586A CN107405325B CN 107405325 B CN107405325 B CN 107405325B CN 201680015586 A CN201680015586 A CN 201680015586A CN 107405325 B CN107405325 B CN 107405325B
Authority
CN
China
Prior art keywords
ppar
compound
liver
alpha
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680015586.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405325A (zh
Inventor
M·普鲁赞斯基
卢西亚诺·阿多里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Ag
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107405325(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CN107405325A publication Critical patent/CN107405325A/zh
Application granted granted Critical
Publication of CN107405325B publication Critical patent/CN107405325B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680015586.6A 2015-02-06 2016-02-05 用于组合疗法的药物组合物 Active CN107405325B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
US62/113,134 2015-02-06
PCT/US2016/016694 WO2016127019A2 (en) 2015-02-06 2016-02-05 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
CN107405325A CN107405325A (zh) 2017-11-28
CN107405325B true CN107405325B (zh) 2021-11-12

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015586.6A Active CN107405325B (zh) 2015-02-06 2016-02-05 用于组合疗法的药物组合物

Country Status (30)

Country Link
US (5) US11311557B2 (enExample)
EP (2) EP4035665A1 (enExample)
JP (2) JP7306791B2 (enExample)
KR (1) KR20170115071A (enExample)
CN (1) CN107405325B (enExample)
AR (1) AR103624A1 (enExample)
AU (2) AU2016215179B2 (enExample)
BR (1) BR112017016766B1 (enExample)
CA (1) CA2976056C (enExample)
CL (3) CL2017001983A1 (enExample)
CO (1) CO2017007959A2 (enExample)
CR (1) CR20170356A (enExample)
DK (1) DK3253382T3 (enExample)
EA (1) EA036404B1 (enExample)
EC (1) ECSP17057848A (enExample)
ES (1) ES2905872T3 (enExample)
GT (1) GT201700174A (enExample)
IL (2) IL253719B (enExample)
MA (1) MA40814A1 (enExample)
MX (1) MX388508B (enExample)
NI (1) NI201700100A (enExample)
PE (1) PE20180027A1 (enExample)
PH (1) PH12017501384A1 (enExample)
SG (1) SG11201706347SA (enExample)
SV (1) SV2017005512A (enExample)
TN (1) TN2017000344A1 (enExample)
TW (1) TW201628625A (enExample)
UA (1) UA125744C2 (enExample)
WO (1) WO2016127019A2 (enExample)
ZA (1) ZA201706007B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
PL3435996T3 (pl) * 2016-03-31 2025-07-28 Genfit Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
US20220226350A1 (en) * 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
WO2021009332A1 (en) * 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
JP2022548725A (ja) * 2019-09-20 2022-11-21 レネオ ファーマシューティカルズ，インク． 腎臓病の治療におけるｐｐａｒデルタアゴニストの使用
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2024132001A1 (en) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases
WO2025250918A1 (en) * 2024-05-30 2025-12-04 Intercept Pharmaceuticals, Inc. Novel compositions
EP4725479A1 (en) * 2024-10-09 2026-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Ppar agonists for treatment of diseases associated with aatd
US20260207538A1 (en) * 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248916A (zh) * 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
WO2000049992A2 (en) * 1999-02-25 2000-08-31 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
US20080096921A1 (en) * 2006-10-24 2008-04-24 Smithkline Beecham Corporation Farnesoid x receptor agonists
CN101522703A (zh) * 2006-06-27 2009-09-02 英特塞普特医药品公司 胆酸派生物作为fxr配基预防或治疗fxr-介导的疾病或状况

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (enExample) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (enExample) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (enExample) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69329894T2 (de) 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
YU2700A (sh) * 1997-08-29 2002-06-19 Pfizer Products Inc. Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
BR9812772A (pt) 1997-10-27 2000-10-10 Reddy Research Foundation "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos"
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
EP1140036A2 (en) 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
AR028023A1 (es) 2000-04-19 2003-04-23 Borody Thomas J Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
DE60107449T2 (de) 2000-09-18 2005-12-08 Glaxo Group Ltd., Greenford Substituierte aminopropoxyarylderivate als lxr agonisten
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
AU2007230989A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
WO2008015763A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2441665T3 (es) * 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248916A (zh) * 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
WO2000049992A2 (en) * 1999-02-25 2000-08-31 The Regents Of The University Of California USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
CN101522703A (zh) * 2006-06-27 2009-09-02 英特塞普特医药品公司 胆酸派生物作为fxr配基预防或治疗fxr-介导的疾病或状况
US20080096921A1 (en) * 2006-10-24 2008-04-24 Smithkline Beecham Corporation Farnesoid x receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"法呢醇X受体激动剂研究进展";贾薇;《中国药物化学杂志》;20100116;第20卷(第1期);第64-69页 *

Also Published As

Publication number Publication date
EA036404B1 (ru) 2020-11-06
DK3253382T3 (da) 2022-02-14
CA2976056A1 (en) 2016-08-11
SV2017005512A (es) 2018-06-12
UA125744C2 (uk) 2022-06-01
WO2016127019A3 (en) 2016-11-03
EP3253382A4 (en) 2018-10-31
TW201628625A (zh) 2016-08-16
MX388508B (es) 2025-03-20
PE20180027A1 (es) 2018-01-09
JP7306791B2 (ja) 2023-07-11
AU2016215179B2 (en) 2021-02-25
AU2016215179A1 (en) 2017-08-24
EP4035665A1 (en) 2022-08-03
IL253719A0 (en) 2017-09-28
MA40814A1 (fr) 2019-08-30
CR20170356A (es) 2018-02-28
GT201700174A (es) 2018-11-13
BR112017016766A2 (en) 2018-04-10
MX2017010131A (es) 2017-11-01
AU2021201015A1 (en) 2021-03-11
US20250367217A1 (en) 2025-12-04
US20220280534A1 (en) 2022-09-08
ECSP17057848A (es) 2017-10-31
CO2017007959A2 (es) 2017-10-31
TN2017000344A1 (en) 2019-01-16
IL290823A (en) 2022-04-01
JP2022000483A (ja) 2022-01-04
BR112017016766B1 (pt) 2023-11-07
KR20170115071A (ko) 2017-10-16
US20180008616A1 (en) 2018-01-11
US20250367216A1 (en) 2025-12-04
WO2016127019A2 (en) 2016-08-11
EP3253382B1 (en) 2021-11-17
US11311557B2 (en) 2022-04-26
CL2018003604A1 (es) 2019-02-22
HK1246191A1 (zh) 2018-09-07
JP2018504438A (ja) 2018-02-15
PH12017501384A1 (en) 2018-01-08
CL2017001983A1 (es) 2018-04-20
IL253719B (en) 2022-04-01
CL2018001006A1 (es) 2018-06-15
ZA201706007B (en) 2019-01-30
NI201700100A (es) 2018-09-06
CA2976056C (en) 2024-02-06
ES2905872T3 (es) 2022-04-12
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
CN107405325A (zh) 2017-11-28
AR103624A1 (es) 2017-05-24
EA201791770A1 (ru) 2017-12-29
EP3253382A2 (en) 2017-12-13
SG11201706347SA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20250367216A1 (en) Pharmaceutical compositions for combination therapy
EA037330B1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
CN107613986A (zh) 用于组合疗法的药物组合物
EP3585374B1 (en) Combination of a ppar agonist with a fxr agonist
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12290498B2 (en) Methods of treatment of cholestatic diseases
KR20210079275A (ko) 고콜레스테롤 관련 병으로 치료 받고 있는 환자에서의 당뇨병의 위험 감소 방법
HK1246191B (en) Pharmaceutical compositions for combination therapy
JP7719476B2 (ja) Ｃｂｐ／カテニン阻害剤の肝線維症治療レジメン
US12377066B2 (en) Treatment of diseases associated with biliary system destruction
TWI710374B (zh) 降脂組成物及其用途
CN121154625A (zh) 5-甲氧基邪蒿素在制备用于预防和/或治疗胆汁淤积性肝病的药物中的应用
Shepherd What is the best way to manage dyslipidemia?

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246191

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: New jersey, USA

Patentee after: INTERCEPT PHARMACEUTICALS, Inc.

Address before: New York, United States

Patentee before: INTERCEPT PHARMACEUTICALS, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20260318

Address after: Bologna, Italy

Patentee after: Alpha Sigma AG

Country or region after: Italy

Address before: new jersey

Patentee before: INTERCEPT PHARMACEUTICALS, Inc.

Country or region before: U.S.A.